[ad_1]
MELBOURNE, Australia and INDIANAPOLIS, January 8, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Dr. Christian Behrenbruch, Group Managing Director and CEO, will make a presentation at the 44th JP Morgan Healthcare Annual Conference to be held in San Francisco, California (United States).
Telix will host a presentation on Monday, January 12 at 9:00 a.m. PST (12:00 p.m. EST / 4:00 a.m. AEDT, January 13), providing an overview of the company’s pipeline assets as well as its commercial portfolio.
The event will be broadcast live on the web here and available on request for 30 days via the Telix Investor Relations website at: ir.telixpharma.com/
In addition to the live presentation and slides, Telix will publish a comprehensive overview of all therapeutic assets in the pipeline in a dedicated presentation accessible on the Investor Relations website.
Financial data for the fourth quarter of 2025 will be released on January 20, 2026.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceutical products and related medical technologies. Telix is headquartered in Melbourne, Australia, and has international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for more information about Telix, including details of the latest share price, ASX and Securities and Exchange Commission (SEC) filings, investor and analyst presentations, press releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X And Facebook.
Telix Investor Relations (global)
Ms Kyahn Williamson
Telix Pharmaceuticals Limited
Senior Vice President of Investor Relations and Corporate Communications
E-mail: kyahn.williamson@telixpharma.com
UNITED STATES
Annie Kasparian
Telix Pharmaceuticals Limited
Director of Investor Relations and Corporate Communications
E-mail: annie.kasparian@telixpharma.com
Media contact
Eliza Grindstone
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com
Legal notices
Cautionary Note Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), the United States Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this press release does not constitute an offer to subscribe, invitation or recommendation with respect to the securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notice. To the extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as discussed below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made regarding the accuracy or completeness of the information contained or opinions expressed during this announcement.
This announcement may contain forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements generally can be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar words or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are based on Telix’s good faith assumptions about the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, as well as Telix’s research and development programs; Telix’s ability to advance, enroll and successfully complete product candidates in clinical studies, including multinational clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned new NDA submission for TLX101-CDx and the planned new BLA submission for TLX250-CDx, manufacturing activities and product commercialization activities; Telix’s sales, marketing, distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; The financial performance of Telix; developments related to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; as well as the pricing and reimbursement of Telix product candidates, if and after their approval. Telix’s actual results, performance or achievements may differ materially from those expressed or implied by such statements, and the differences may be adverse. Therefore, you should not place undue reliance on these forward-looking statements.
Trademarks and trade names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate a waiver of rights on the part of Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend that the use or display of third party trademarks or trade names to imply any affiliation, endorsement or sponsorship by such third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
View original content to download multimedia:^ https://www.prnewswire.com/apac/news-releases/telix-to-present-pipeline-and-commercial-portfolio-overview-at-jp-morgan-healthcare-conference-302656128.html
SOURCE Telix Pharmaceuticals Limited
[ad_2]
Source: PR Newswire
